BTIM Stock News, BioTime CEO Dr. Michael West to Present at World Stem Cells & Regenerative Medicine Congress 2009 and Discuss New Cell Lines with Cartilage-Forming Potential
BioTime, Inc. (OTCBB: BTIMstock news) Chief Executive Officer Michael West, Ph.D.
will deliver a presentation on May 14, 2009 at the World
Stem Cells and Regenerative Medicine Congress meeting in London. Dr.
West’s presentation is titled “Opportunities and Challenges of
Commercializing Stem Cell Research.”
This year’s conference will focus on a broad array of topics related to
stem cell research, including the biology, medicine, applications,
regulation, and business of Stem Cells. Dr. West’s presentation will
include a description of BioTime’s stem cell research programs that are
focused on opportunities for near-term revenues in the development and
marketing of cell lines.
Dr. West will also discuss for the first time data relating to
progenitor cell lines, produced using BioTime’s ACTCellerate™
technology, that exhibit markers for becoming cartilage cells. Embryonic
progenitor cells that produce cartilage might have a use in the
development of treatments for orthopedic diseases such as arthritis and
degenerative diseases of the spine.
Dr. West’s presentation will be available online at http://www.biotimeinc.com/
on May 13, 2009.
BioTime, headquartered in Alameda, California, is a biotechnology
company focused on the emerging field of regenerative medicine.
BioTime's lead product, Hextend®, is a blood plasma expander
used in surgery, emergency trauma treatment and other applications.
Hextend is manufactured and distributed in the U.S. by Hospira, Inc. and
in South Korea by CJ CheilJedang Corp. under exclusive licensing
agreements.
BioTime markets its stem cell research products through its wholly owned
subsidiary Embryome
Sciences, Inc. which is developing new medical and research products
using embryonic stem cell technology. Additional information about
BioTime can be found on the web at www.biotimeinc.com.
Hextend®, ESpyTM, and ESpanTM, are
trademarks of BioTime, Inc.
Forward-Looking Statements
Statements pertaining to future financial and/or operating results,
future growth in research, technology, clinical development and
potential opportunities for the company and its subsidiary, along with
other statements about the future expectations, beliefs, goals, plans,
or prospects expressed by management constitute forward-looking
statements. Any statements that are not historical fact (including, but
not limited to statements that contain words such as “will,” “believes,”
“plans,” “anticipates,” “expects,” “estimates,”) should also be
considered to be forward-looking statements. Forward-looking statements
involve risks and uncertainties, including, without limitation, risks
inherent in the development and/or commercialization of potential
products, uncertainty in the results of clinical trials or regulatory
approvals, need and ability to obtain future capital, and maintenance of
intellectual property rights. Actual results may differ materially from
the results anticipated in these forward-looking statements and as such
should be evaluated together with the many uncertainties that affect the
company's business, particularly those mentioned in the cautionary
statements found in the company's Securities and Exchange Commission
filings. The company disclaims any intent or obligation to update these
forward-looking statements.
To receive ongoing BioTime corporate communications, please click on the
following link to join our email alert list: http://www.b2i.us/irpass.asp?BzID=1152&to=ea&s=0
